Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE